Functional proteomics outlines the complexity of breast cancer molecular subtypes
暂无分享,去创建一个
P. Maín | H. Navarro | E. Espinosa | J. Grossmann | N. Selevsek | J. Feliu | P. Nanni | J. M. Arevalillo | L. Trilla-Fuertes | A. Gámez-Pozo | G. Prado-Vázquez | A. Zapater-Moros | R. López-Vacas | M. Díaz-Almirón | P. Zamora | Juan Ángel Fresno Vara | E. Ciruelos | P. Martínez del Prado | Julia Berges-Soria | R. Gómez Rioja | F. Gayá Moreno
[1] M. Zabel,et al. Prolactin-induced protein as a potential therapy response marker of adjuvant chemotherapy in breast cancer patients. , 2016, American journal of cancer research.
[2] P. Maín,et al. Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications. , 2015, Cancer research.
[3] P. Hall,et al. Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer , 2015, Clinical Proteomics.
[4] L. Pusztai,et al. Multigene prognostic tests in breast cancer: past, present, future , 2015, Breast Cancer Research.
[5] Christopher R. Myers,et al. A robust and efficient method for estimating enzyme complex abundance and metabolic flux from expression data , 2014, Comput. Biol. Chem..
[6] C. Denkert,et al. Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes , 2014, BMC Cancer.
[7] A. Naderi,et al. Prolactin-induced protein is required for cell cycle progression in breast cancer. , 2014, Neoplasia.
[8] Toshima Z. Parris,et al. Additive effect of the AZGP1, PIP, S100A8 and UBE2C molecular biomarkers improves outcome prediction in breast carcinoma , 2014, International journal of cancer.
[9] J. M. Jerez,et al. A microRNA Signature Associated with Early Recurrence in Breast Cancer , 2014, PloS one.
[10] S. K. Baniwal,et al. Prolactin-Induced Protein (PIP) Regulates Proliferation of Luminal A Type Breast Cancer Cells in an Estrogen-Independent Manner , 2013, PloS one.
[11] C. Denkert,et al. Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes , 2014, BMC Cancer.
[12] Keerthana Krishnan,et al. miR-139-5p is a regulator of metastatic pathways in breast cancer , 2013, RNA.
[13] Jian Weng,et al. Cavin-3 dictates the balance between ERK and Akt signaling , 2013, eLife.
[14] G. Tse,et al. Expression of mammaglobin and gross cystic disease fluid protein-15 in breast carcinomas. , 2013, Human pathology.
[15] E. Espinosa,et al. Shotgun proteomics of archival triple‐negative breast cancer samples , 2013, Proteomics. Clinical applications.
[16] Ronan M. T. Fleming,et al. A community-driven global reconstruction of human metabolism , 2013, Nature Biotechnology.
[17] C. la Vecchia,et al. European cancer mortality predictions for the year 2014. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] Jin-hai Tang,et al. miR-342 is associated with estrogen receptor-α expression and response to tamoxifen in breast cancer , 2013, Experimental and therapeutic medicine.
[19] Raphaël Porcher,et al. Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15 , 2013, Breast Cancer Research.
[20] G. Sauter,et al. Clinical Relevance of Loss of 11p15 in Primary and Metastatic Breast Cancer: Association with Loss of PRKCDBP Expression in Brain Metastases , 2012, PloS one.
[21] G. Mills,et al. Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer , 2012, Breast Cancer Research.
[22] A. Naderi,et al. Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer , 2012, Breast Cancer Research.
[23] Kikuya Kato,et al. Strategy for SRM-based verification of biomarker candidates discovered by iTRAQ method in limited breast cancer tissue samples. , 2012, Journal of proteome research.
[24] J. Mefford,et al. Stromal Genes Add Prognostic Information to Proliferation and Histoclinical Markers: A Basis for the Next Generation of Breast Cancer Gene Signatures , 2012, PloS one.
[25] Jürgen Cox,et al. Super-SILAC Allows Classification of Diffuse Large B-cell Lymphoma Subtypes by Their Protein Expression Profiles* , 2012, Molecular & Cellular Proteomics.
[26] Moyez Dharsee,et al. Proteomic Analyses Reveal High Expression of Decorin and Endoplasmin (HSP90B1) Are Associated with Breast Cancer Metastasis and Decreased Survival , 2012, PloS one.
[27] F. Bertucci,et al. A refined molecular taxonomy of breast cancer , 2011, Oncogene.
[28] Charles M. Perou,et al. Practical implications of gene-expression-based assays for breast oncologists , 2012, Nature Reviews Clinical Oncology.
[29] Jeffrey T. Chang,et al. Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer , 2012, Breast Cancer Research.
[30] Suzy V. Torti,et al. An iron regulatory gene signature predicts outcome in breast cancer. , 2011, Cancer research.
[31] Pablo C. Echeverría,et al. An Interaction Network Predicted from Public Data as a Discovery Tool: Application to the Hsp90 Molecular Chaperone Machine , 2011, PloS one.
[32] E. Espinosa,et al. Protein phosphorylation analysis in archival clinical cancer samples by shotgun and targeted proteomics approaches. , 2011, Molecular bioSystems.
[33] C. la Vecchia,et al. European cancer mortality predictions for the year 2011. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] M. Mann,et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. , 2011, Journal of proteome research.
[35] Ronan M. T. Fleming,et al. Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0 , 2007, Nature Protocols.
[36] C. Castañeda,et al. The present and future of gene profiling in breast cancer , 2011, Cancer and Metastasis Reviews.
[37] P. M. Das,et al. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors , 2010, Molecular Cancer.
[38] Per Karlsson,et al. Clinical Implications of Gene Dosage and Gene Expression Patterns in Diploid Breast Carcinoma , 2010, Clinical Cancer Research.
[39] E. Espinosa,et al. Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen and formalin-fixed, paraffin-embedded breast cancer tissues. , 2010, BioTechniques.
[40] Brendan MacLean,et al. Bioinformatics Applications Note Gene Expression Skyline: an Open Source Document Editor for Creating and Analyzing Targeted Proteomics Experiments , 2022 .
[41] Jeffrey D Orth,et al. What is flux balance analysis? , 2010, Nature Biotechnology.
[42] Pilar Zamora,et al. An 8-gene qRT-PCR-based gene expression score that has prognostic value in early breast cancer , 2010, BMC Cancer.
[43] David Edwards,et al. High-dimensional Graphical Model Search with gRapHD R Package , 2009, 0909.1234.
[44] Lukas N. Mueller,et al. Full Dynamic Range Proteome Analysis of S. cerevisiae by Targeted Proteomics , 2009, Cell.
[45] Desmond S. Lun,et al. Interpreting Expression Data with Metabolic Flux Models: Predicting Mycobacterium tuberculosis Mycolic Acid Production , 2009, PLoS Comput. Biol..
[46] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] Brad T. Sherman,et al. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.
[48] Christophe Lemetre,et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer , 2009, Breast Cancer Research.
[49] M. Mann,et al. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.
[50] Tyler E. Miller,et al. MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1*♦ , 2008, Journal of Biological Chemistry.
[51] Henry H. N. Lam,et al. PeptideAtlas: a resource for target selection for emerging targeted proteomics workflows , 2008, EMBO reports.
[52] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.
[53] R. Deberardinis,et al. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis , 2007, Proceedings of the National Academy of Sciences.
[54] H. Nevanlinna,et al. Mast cells and eosinophils in invasive breast carcinoma , 2007, BMC Cancer.
[55] György Marko-Varga,et al. Personalized medicine and proteomics: lessons from non-small cell lung cancer. , 2007, Journal of proteome research.
[56] G. D’Arrigo,et al. Mast cells in invasive ductal breast cancer: different behavior in high and minimum hormone-receptive cancers. , 2007, Anticancer research.
[57] Yuval Kluger,et al. High HSP90 expression is associated with decreased survival in breast cancer. , 2007, Cancer research.
[58] S. Leung,et al. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases , 2007, Breast Cancer Research and Treatment.
[59] S. Somiari,et al. Proteomics in human cancer research , 2007, Proteomics. Clinical applications.
[60] Cheng Li,et al. Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.
[61] A. Nobel,et al. Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .
[62] Steven A Carr,et al. Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.
[63] A. Nobel,et al. The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.
[64] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[65] D. Huntsman,et al. The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis , 2004, Modern Pathology.
[66] Richard Simon,et al. A random variance model for detection of differential gene expression in small microarray experiments , 2003, Bioinform..
[67] P. Shannon,et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.
[68] A I Saeed,et al. TM4: a free, open-source system for microarray data management and analysis. , 2003, BioTechniques.
[69] S. Hanash. Disease proteomics : Proteomics , 2003 .
[70] S. Hanash,et al. Disease proteomics , 2003, Nature.
[71] Peter H Watson,et al. Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[72] M. Radmacher,et al. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. , 2003, Journal of the National Cancer Institute.
[73] Van,et al. A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.
[74] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[75] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[76] Luis Moroder,et al. Structure of TPR Domain–Peptide Complexes Critical Elements in the Assembly of the Hsp70–Hsp90 Multichaperone Machine , 2000, Cell.
[77] G. Schwarz. Estimating the Dimension of a Model , 1978 .